Novel rescue therapy for C4d-positive acute humoral renal allograft rejection


    loading  Checking for direct PDF access through Ovid

Abstract

ObjectiveTo investigate the efficacy of immunoadsorption (IA) in combination with tacrolimus (TAC) and mycophenolate mofetil (MMF) rescue therapy for C4d-positive acute humoral rejection (AHR) of renal transplants.MethodologySix of 185 cadaveric renal allograft recipients transplanted at our institute developed AHR over a mean period of 4.8 ± 0.8 d after operation. The ages ranged from 35 to 51 yr (mean 42.6 ± 5.6 yr). C4d deposits in peritubular capillaries (PTC) and accumulation of granulocytes in PTC were observed. IA with staphylococcal protein A and TAC–MMF combination therapy were given.ResultsAfter subjected to IA for 6.3 ± 1.03 sessions combined with TAC (0.14–0.16 mg/kg/d) and MMF (1.5 g/d) therapy, renal function recovered in all the patients. The mean duration of treatment when serum creatinine decreased was 14 ± 2.9 d. The pre-IA panel reactive antibody reactivity was as high as 50.2 ± 6.1%, and was significantly reduced to 8.3 ± 2.9% after IA. Repeated allograft kidney biopsy in four of six patients revealed a favorable remission of AHR. With a mean follow-up of 18.8 ± 5.46 months, patient and allograft survival are 100%, renal function remained stable with a mean serum creatinine of 1.2 ± 0.22 mg/dL.ConclusionThe optimal treatment for alloantibody-mediated AHR remains undefined. Our findings suggest that a therapeutic approach combining IA and TAC–MMF rescue has excellence to improve the outcome of AHR.

    loading  Loading Related Articles